Ramistar 10mg

Ramistar (ramipres)

Ramistar 10 mg is a prescription drug and should be taken when advised by a doctor. Ramipril 10 mg is the main active component of Ramistar (Ramipres), which belongs to the group of medicines called Antihypertensives. Ramistar or Ramipres is utilized for multiple indications, which include hypertension (high blood pressure) and prevention of heart failure progression following a myocardial infarction (MI). It is also effective at reducing the risk of MI, stroke, and mortality in patients who are older than 55 years old with an increased risk of atherosclerotic disease and major adverse cardiac events. 

1.  In treatment of hypertension

Ramipril 10 mg is used for the treatment of hypertension. It may be given as a monotherapy or in combination with other antihypertensive agents as a combination therapy, particularly with thiazide diuretics, to attain a target systolic and diastolic blood pressure in patients. The treatment helps to manage blood pressure levels by preventing the mortalities and morbidities related to high blood pressure.

2.  Reduction in the risk of myocardial infarction (heart attack), stroke, and death-associated cardiovascular issues

Ramipril is used in patients 55 years or older who are at high risk of developing major heart disease because of a history of peripheral vascular disease, coronary artery disease (CAD), stroke, or diabetes mellitus that comes with at least one other cardiovascular risk factor (increased total cholesterol levels,  low high-density lipoprotein levels,  high blood pressure,   or cigarette smoking to reduce the risk of heart attack, stroke, or death from heart-related causes. The medication can be combined with other treatments such as antiplatelet, antihypertensive, or lipid-lowering therapy.

3.  In heart failure post-myocardial infarction

This drug is utilized in stable patients who show clinical signs of congestive heart failure within the first few days of experiencing an acute myocardial infarction. This medication, when given to such patients, has been shown to cause a significant reduction in the risk of death and a decline in the risk of failure-related hospitalization and progression to severe/resistant heart failure.